Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Jixin Fan, Runqing Lu, Jingkui Zhu, Xiao Guo, Dingming Wan, Xinsheng Xie, Weijie Cao, Yinyin Zhang, Haiqiu Zhao, Yingmei Li, Rongqun Guo, Zhongxing Jiang, Yongping Song, Fei He, Rong Guo
In adults with acute lymphoblastic leukemia (ALL), post-transplant relapse is a major risk factor for mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our study investigated the efficacy and safety of decitabine (dec) with ALL patients post-transplantation. We performed a retrospective cohort study to assess the efficacy of decitabine (dec) with post-transplant ALL at the First Affiliated Hospital of Zhengzhou University from February 2016 to September 2021. A total of 141 consecutive ALL patients were analyzed and divided into decitabine (dec, n = 65) and control (ctrl, n = 76) groups based on whether they were treated with decitabine after allo-HSCT...
March 24, 2023: Bone Marrow Transplantation
#2
JOURNAL ARTICLE
Majed Altareb, Moheeb Al-Awwami, Feras Alfraih, Saud Alhayli, Syed Osman Ahmed, Marwan Shaheen, Naeem Chaudhri, Fahad Alsharif, Hana Alkhabbaz, Abdulwahab A Albabtain, Mansour Alfayez, Amr Hanbali, Alfadel Alshaibani, Ahmad S Alotaibi, Walid Rasheed, Amal Algharably, Fahad Almohareb, Ali Alahmari, Hazzaa Alzahrani, Mahmoud Aljurf, Riad El Fakih
PGF is a devastating complication after allogeneic transplant. We retrospectively analyzed our haploidentical transplant registry to report the incidence and impact of DSA and anti-HLA on engraftment. 107 patients were identified. Median recipient-age of 22, median donor-age of 31. Sixty-two patients had AML (58%), 29 had ALL (27%), 16 (15%) had other malignancies. Sixty-one recipients (57%) had positive anti-HLA, 56 of them had the DSA results available, of these 17 patients had DSAs (15% of the total number of patients, or 28% of patients who have anti-HLA antibodies)...
March 23, 2023: Bone Marrow Transplantation
#3
LETTER
Maxime Jullien, Amandine Le Bourgeois, Pierre Peterlin, Alice Garnier, Thierry Guillaume, Marie C Béné, Patrice Chevallier
No abstract text is available yet for this article.
March 23, 2023: Bone Marrow Transplantation
#4
LETTER
M A de Witte, J E Mooyaart, J D Hoogenboom, C Chabannon, F Malard, A Ruggeri, J Kuball
No abstract text is available yet for this article.
March 18, 2023: Bone Marrow Transplantation
#5
LETTER
David M Chooljian, Jeremy W Jacobs, Brian D Adkins, Bipin N Savani, Lorin A Bibb, Garrett S Booth
No abstract text is available yet for this article.
March 15, 2023: Bone Marrow Transplantation
#6
JOURNAL ARTICLE
Alberto Mussetti, Leyre Bento, Mariana Bastos-Oreiro, B Rius Sansalvador, Carmen Albo, Rebeca Bailen, Pere Barba, Ana Benzaquén, Javier Briones, Ana Carolina Caballero, António Campos, Ignacio Español, Christelle Ferra, Sebastián Garzón López, Pedro Antonio González Sierra, Luisa Maria Guerra, Rafael Hernani, Gloria Iacoboni, Ana Isabel Jiminez Ubieto, Mi Kwon, Lucía López Corral, Oriana López-Godino, Maria Carmen Martinez Munoz, Nuria Martínez-Cibrián, Juan Montoro Gómez, Laura Pérez-Ortega, Guillermo Ortí, Valentín Ortiz-Maldonado, Maria-Jesús Pascual, María Perera, Antonio Perez, Juan Luis Reguera, Jose M Sanchez, Jaime Sanz, Anna Torrent, Lucrecia Yáñez, Rosario Varela, Izaksun Ceberio Echechipia, Dolores Caballero, Anna Sureda
Anti-CD19 chimeric antigen receptor T cells (CART) has rapidly been adopted as the standard third-line therapy to treat aggressive B-cell lymphomas (ABCL) after failure of second-line therapy despite the lack of direct comparisons with allogeneic hematopoietic cell transplantation (alloHCT)-based strategies. Using the Grupo Español de Trasplante y Terapia Celular (GETH-TC) registry, we selected patients with the following characteristics: CART or alloHCT performed between 2016 and 2021; ≥18 years old; ABCL diagnosis; ≥2 lines of therapy; and either anti-CD19 CART or alloHCT as therapy at relapse...
March 14, 2023: Bone Marrow Transplantation
#7
JOURNAL ARTICLE
Jean El Cheikh, Ghassan Bidaoui, Ali Atoui, Khodr Terro, Layal Sharrouf, Ammar Zahreddine, Nour Moukalled, Imane Abou Dalle, Ali Bazarbachi, Mohamad Mohty, Remy Dulery
Clofarabine (Clo) is an immunosuppressive purine analog that may have better anti-leukemic activity than fludarabine (Flu). The addition of total body irradiation (TBI) to conditioning regimens has been widely investigated. However, the use of single agent Clo in combination with intermediate doses of TBI ranging from 4 to 8 Gy has not been studied yet. This study is a double center, observational, retrospective study of patients with high-risk hematological malignancies diagnosed from 2012 to 2021, treated at the American University of Beirut Medical Center in Beirut (AUBMC), Lebanon, and Saint-Antoine Hospital (SAH) in Paris, France...
March 13, 2023: Bone Marrow Transplantation
#8
JOURNAL ARTICLE
Riccardo Saccardi, Hein Putter, Dirk-Jan Eikema, María Paula Busto, Eoin McGrath, Bas Middelkoop, Gillian Adams, Marina Atlija, Francis Ayuketang Ayuk, Helen Baldomero, Yves Beguin, Rafael de la Cámara, Ángel Cedillo, Anna María Sureda Balari, Christian Chabannon, Selim Corbacioglu, Harry Dolstra, Rafael F Duarte, Rémy Dulery, Raffaella Greco, Andreu Gusi, Nada Hamad, Michelle Kenyon, Nicolaus Kröger, Myriam Labopin, Julia Lee, Per Ljungman, Lynn Manson, Florence Mensil, Noel Milpied, Mohamad Mohty, Elena Oldani, Kim Orchard, Jakob Passweg, Rachel Pearce, Régis Peffault de Latour, Hélène A Poirel, Tuula Rintala, J Douglas Rizzo, Annalisa Ruggeri, Carla Sanchez-Martinez, Fermin Sanchez-Guijo, Isabel Sánchez-Ortega, Marie Trnková, David Valcárcel Ferreiras, Leonie Wilcox, Liesbeth C de Wreede, John A Snowden
From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual EBMT Centers with a means of quality-assuring the HSCT process and meeting FACT-JACIE accreditation requirements relating to 1-year survival outcomes. Informed by previous experience from Europe, North America and Australasia, the Clinical Outcomes Group (COG) established criteria for patient and Center selection, and a set of key clinical variables within a dedicated statistical model adapted to the capabilities of the EBMT Registry...
March 9, 2023: Bone Marrow Transplantation
#9
JOURNAL ARTICLE
Jakob R Passweg, Helen Baldomero, Fabio Ciceri, Selim Corbacioglu, Rafael de la Cámara, Harry Dolstra, Bertram Glass, Raffaella Greco, Donal P McLornan, Bénédicte Neven, Régis Peffault de Latour, Zinaida Perić, Annalisa Ruggeri, John A Snowden, Anna Sureda
In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 patients received advanced cellular therapies, 2524 of which were CAR-T treatments, an additional 3245 received DLI. Changes compared to the previous year were CAR-T treatment (+35%), allogeneic HCT +5.4%, autologous HCT +3.9%, more pronounced in non-malignant disorders. Main indications for allogeneic HCT were myeloid malignancies 10,745 (58%), lymphoid malignancies 5127 (28%) and non-malignant disorders 2501 (13%)...
March 6, 2023: Bone Marrow Transplantation
#10
EDITORIAL
Raphael A Fraser
We are pleased to add this typescript, Inappropriate use of statistical power by Raphael Fraser to the BONE MARROW TRANSPLANTATION Statistics Series. The authour discusses how we sometimes misuse statistical analyses after a study is completed and analyzed to explain the results. The most egregious example is post hoc power calculations.When the conclusion of an observational study or clinical trial is negative, namely, the data observed (or more extreme data) fail to reject the null hypothesis, people often argue for calculating the observed statistical power...
March 3, 2023: Bone Marrow Transplantation
#11
JOURNAL ARTICLE
Kirsten Alexandra Eberhardt, Verena Jung, Elena Knops, Eva Heger, Maike Wirtz, Gertrud Steger, Rolf Kaiser, Patrick Affeldt, Udo Holtick, Florian Klein, Christof Scheid, Veronica Di Cristanziano
Cytomegalovirus (CMV) represents one of the most common infectious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, a common diagnostic test used to stratify the risk for CMV infection in allo-HSCT recipients is the qualitative CMV serology of donor and recipient. A positive serostatus of the recipient is the most important risk factor for CMV reactivation and associated with reduced overall survival post-transplantation (TX). Direct and indirect effects of CMV are involved in the poorer survival outcome...
March 3, 2023: Bone Marrow Transplantation
#12
LETTER
Andrea Warthmann, Andreas Holbro, Andreas Buser, Stefan Schefer, Sabine Degen Kellerhals, Miriam Ravelli, Jakob Passweg, Georg Stussi, Jörg Halter
No abstract text is available yet for this article.
March 1, 2023: Bone Marrow Transplantation
#13
JOURNAL ARTICLE
José Luis Piñana, Rodrigo Martino, Lourdes Vazquez, Lucia López-Corral, Ariadna Pérez, Pedro Chorão, Alejandro Avendaño-Pita, María-Jesús Pascual, Andrés Sánchez-Salinas, Gabriela Sanz-Linares, María T Olave, Ignacio Arroyo, Mar Tormo, Lucia Villalon, Venancio Conesa-Garcia, Beatriz Gago, María-José Terol, Marta Villalba, Valentín Garcia-Gutierrez, Almudena Cabero, José Ángel Hernández-Rivas, Elena Ferrer, Irene García-Cadenas, Anabel Teruel, David Navarro, Ángel Cedillo, Anna Sureda, Carlos Solano
The kinetics of SARS-CoV-2 reactive IgG antibodies after full vaccination and booster in allogeneic and autologous stem cell transplantation (allo-HSCT, ASCT) and chimeric antigen receptor T-cell therapy (CAR-T) are of utmost importance for estimating risk of infection. A prospective multicenter registry-based cohort study, conducted from December 2020 to July 2022 was used to analyze antibody waning over time, booster effect and the relationship of antibody response and breakthrough infection in 572 recipients (429 allo-HSCT, 121 ASCT and 22 CAR-T cell therapy)...
February 28, 2023: Bone Marrow Transplantation
#14
REVIEW
N Aghel, M Lui, V Wang, D Khalaf, H Mian, C Hillis, I Walker, B Leber, J H Lipton, M Aljama, K Lepic, T Berg, A Garcia-Horton, J Petropoulos, H Masoom, D P Leong
Cardiovascular diseases are an emerging cause of mortality and morbidity in survivors of hematopoietic stem cell transplantation (HSCT); however, the incidence of cardiovascular events (CVEs) in this population is not well described. This systematic review summarizes the evidence on the incidence of CVEs in HSCT recipients. Medline and Embase were searched from inception to December 2020. Inclusion criteria were cohort studies and phase 3 randomized controlled trials that reported CVEs among adults who underwent HSCT for hematological malignancies...
February 27, 2023: Bone Marrow Transplantation
#15
JOURNAL ARTICLE
Dina Averbuch, Rafael de la Camara, Gloria Tridello, Nina Simone Knelange, Tatiana A Bykova, Marianne Ifversen, Veronika Dobsinska, Mouhab Ayas, Amir Ali Hamidieh, Herbert Pichler, Antonio Perez-Martinez, Simone Cesaro, Mikael Sundin, Isabel Badell, Peter Bader, Jan-Erik Johansson, Oana Mirci-Danicar, Petr Sedlacek, Catherine Paillard, Brenda Gibson, Sarah Lawson, Nicolaus Kroeger, Selim Corbacioglu, Malgorzata Mikulska, Jose Luis Piñana, Jan Styczynski, Per Ljungman
Risk factors for severe SARS-Cov-2 infection course are poorly described in children following hematopoietic cell transplantation (HCT). In this international study, we analyzed factors associated with a severe course (intensive care unit (ICU) admission and/or mortality) in post-HCT children. Eighty-nine children (58% male; median age 9 years (min-max 1-18)) who received an allogeneic (85; 96%) or an autologous (4; 4%) HCT were reported from 28 centers (18 countries). Median time from HCT to SARS-Cov-2 infection was 7 months (min-max 0-181)...
February 27, 2023: Bone Marrow Transplantation
#16
LETTER
Anne Hubben, Danai Dima, Tahani Atieh, Chakra Chaulagain, Beth Faiman, Christina Ferraro, Sandra Mazzoni, Louis Williams, Christy Samaras, Jason Valent, Craig Sauter, Faiz Anwer, Jack Khouri
No abstract text is available yet for this article.
February 24, 2023: Bone Marrow Transplantation
#17
LETTER
Luca Vinci, Christian Flotho, Peter Noellke, Dirk Lebrecht, Riccardo Masetti, Valerie de Haas, Barbara De Moerloose, Michael Dworzak, Henrik Hasle, Tayfun Güngör, Jan Starý, Dominik Turkiewicz, Marek Ussowicz, Cristina Diaz de Heredia, Jochen Buechner, Kirsi Jahnukainen, Krisztian Kallay, Ivana Bodova, Owen P Smith, Marco Zecca, Dorine Bresters, Peter Lang, Tania Nicole Masmas, Roland Meisel, Herbert Pichler, Miriam Erlacher, Gudrun Göhring, Franco Locatelli, Brigitte Strahm, Charlotte M Niemeyer, Ayami Yoshimi
No abstract text is available yet for this article.
February 23, 2023: Bone Marrow Transplantation
#18
JOURNAL ARTICLE
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Alexander Kulagin, Hélène Labussière-Wallet, Montserrat Rovira, Didier Blaise, Jan Vydra, Ibrahim Yakoub-Agha, Goda Choi, Péter Reményi, Yener Koc, Jaime Sanz, Fabio Ciceri, Mohamad Mohty
Post-transplant cyclophosphamide (PTCy) is being increasingly used as graft-versus-host disease (GVHD) prophylaxis post allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) transplanted in first complete remission (CR1). However, results may differ in patients transplanted in CR2. We retrospectively evaluated transplant outcomes of adult AML patients transplanted between 2010-2019 from 9-10/10 human leukocyte antigen (HLA)-matched unrelated donor (UD) in CR2...
February 23, 2023: Bone Marrow Transplantation
#19
LETTER
Raffaella Greco, Jorinde D Hoogenboom, Edouard F Bonneville, Achilles Anagnostopoulos, Angela Cuoghi, Jean-Hugues Dalle, Eva M Weissinger, Peter Lang, Federica Galaverna, Massimo Martino, Alexei Maschan, Christine Mauz-Körholz, Maddalena Noviello, Jakob Passweg, Jacopo Peccatori, Montserrat Rovira, Carlos Solano, Hendrik Veelken, Andrea Velardi, Eva Maria Wagner-Drouet, Xi Zhang, Fabio Ciceri, Chiara Bonini, Luca Vago, Annalisa Ruggeri, Christian Chabannon
No abstract text is available yet for this article.
February 22, 2023: Bone Marrow Transplantation
#20
EDITORIAL
Shaun McCann
No abstract text is available yet for this article.
February 16, 2023: Bone Marrow Transplantation
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
